CORAL GABLES, Fla., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it has entered into definitive agreements to sell 8.8 million shares of its common stock in a registered direct public offering. The offering price for each share of common stock is $1.72, resulting in gross proceeds of approximately $15.1 million.